Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 7, 2015Pharmacogenetics and Genomics

The HER2 655 A>G polymorphism was significantly associated with cardiotoxicity (AG+GG versus AA: OR 5.72, 95% CI 1.50-21.76, P=0.01).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does the HER2 655 A>G polymorphism predict trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients?

Population

78 HER2-positive breast cancer patients receiving trastuzumab

Comparison

HER2 655 A>G genetic variant vs HER2 655 AA genotype

Design

Cohort

Follow-up

1 year

Authors

CPCelia Gómez PeñaCDCristina Lucía Dávila-FajardoLMLuis Javier Martínez-González

Discussion

Loading...

Member takes

Overview

Supports HER2 655 A>G as marker for trastuzumab cardiotoxicity; hypothesis-generating, requires validation in larger cohorts.

Structured PICO

Does the HER2 655 A>G polymorphism predict trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients?

P
Population
78 HER2-positive breast cancer patients receiving trastuzumab
I
Intervention
HER2 655 A>G (rs1136201) genetic variant (AG or GG genotype)
C
Comparator
HER2 655 AA genotype
O
Outcome
Occurrence of cardiotoxic events during 1 year after the first infusionsafety

The HER2 655 A>G polymorphism serves as a significant genetic marker for increased risk of trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients.

Cite This Study

Peña et al. (2015) studied this question.

synapsesocial.com/papers/6a7025fa35aa2c282ce1740ehttps://doi.org/10.1097/fpc.0000000000000149
View Full Paper
Ask AI
Bookmark
Share